Matthew E. Korenberg - 20 Sep 2024 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Reporting relationship: President & COO
Issuer ticker: LGND
Reported as of: 20 Sep 2024
Net transaction value: -$878,082
SEC form: 4
Accepted by SEC: 24 Sep 2024, 19:41:15 UTC
Prior SEC filing: 18 Sep 2024
Next SEC filing: 16 Dec 2024
Source filing: View source filing
Reporting owner signature: By: /s/ Andrew Reardon, Attorney-in-Fact For: Matthew E. Korenberg

Key filing fact

Matthew E. Korenberg filed Form 4 for LIGAND PHARMACEUTICALS INC (LGND) on 24 Sep 2024.

Key facts

This page summarizes Matthew E. Korenberg's Form 4 filing for LIGAND PHARMACEUTICALS INC (LGND).
10 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 24 Sep 2024, 19:41.

Change

Previous filing in this sequence was filed on 18 Sep 2024.
Current net transaction value: -$878,082.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LGND transaction

Common Stock

Options Exercise

Transaction value: $249,050
Shares: +4,982
Change %: +9.6%
Price: $49.99
Shares after: 57,052
Date: 20 Sep 2024
Ownership: Direct

LGND transaction

Common Stock

Sale

Transaction value: $653,238
Shares: -6,275
Change %: -11%
Price: $104.10
Shares after: 50,777
Date: 20 Sep 2024
Ownership: Direct
Footnotes: F1

LGND transaction

Common Stock

Options Exercise

Transaction value: $19,746
Shares: +395
Change %: +0.78%
Price: $49.99
Shares after: 51,172
Date: 23 Sep 2024
Ownership: Direct

LGND transaction

Common Stock

Options Exercise

Transaction value: $495,481
Shares: +9,377
Change %: +18%
Price: $52.84
Shares after: 60,549
Date: 23 Sep 2024
Ownership: Direct

LGND transaction

Common Stock

Sale

Transaction value: $248,228
Shares: -2,481
Change %: -4.1%
Price: $100.05
Shares after: 58,068
Date: 23 Sep 2024
Ownership: Direct
Footnotes: F2

LGND transaction

Common Stock

Sale

Transaction value: $720,379
Shares: -7,090
Change %: -12%
Price: $101.60
Shares after: 50,978
Date: 23 Sep 2024
Ownership: Direct
Footnotes: F3

LGND transaction

Common Stock

Sale

Transaction value: $20,513
Shares: -201
Change %: -0.39%
Price: $102.05
Shares after: 50,777
Date: 23 Sep 2024
Ownership: Direct
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LGND transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -4,982
Change %: -93%
Price: $0.000000
Shares after: 395
Date: 20 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,982
Exercise price: $49.99
Footnotes: F5

LGND transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -395
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 23 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 395
Exercise price: $49.99
Footnotes: F5

LGND transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -9,377
Change %: -18%
Price: $0.000000
Shares after: 42,436
Date: 23 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 9,377
Exercise price: $52.84
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 6 footnotes

Footnote F1

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F2

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F4

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F5

This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.

Footnote F6

This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026.